
    
      Total duration of the study per patient is in the range of 17 to 29 weeks.

      This trial is being conducted in China, where the INN designation for the study molecule is
      "aflibercept" and this term is therefore used throughout the synopsis. In the US, the US
      proper name is "ziv-aflibercept".
    
  